Registry for understanding Parkinson's disease in China
The Chinese DENOVO Parkinson's Disease Registry
This study looks at how Parkinson's disease affects patients in China over time to see if certain signs can help predict how the disease will progress.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 30 Years to 75 Years |
| Sex | All |
| Sponsor | Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT05767151 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the clinical characteristics and progression of Parkinson's disease (PD) in a longitudinal cohort of patients in China. It focuses on identifying biomarkers that can predict disease evolution and prognosis, addressing the heterogeneity of PD symptoms and progression rates. Data will be collected at baseline and during routine follow-up visits, including detailed patient histories and environmental factors. The study seeks to enhance understanding of PD's clinical features and potential genetic and environmental influences.
Who should consider this trial
Good fit: Ideal candidates for this study are newly diagnosed Parkinson's disease patients aged 30 to 75 with a disease duration of two years or less.
Not a fit: Patients with cognitive impairment or those already receiving antiparkinsonian therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better prediction of Parkinson's disease progression and more personalized treatment approaches for patients.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for Parkinson's disease, but this specific approach focusing on a Chinese cohort is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants were diagnosed by MDS Clinical Diagnostic Criteria for PD 2. Disease duration ≤ 2 years at baseline 3. Hoehn-Yahr stage ≤2 at baseline 4. The age of PD patients ranges from 30 to 75 years old 5. Participants were naive to antiparkinsonian therapy 6. Able to Written informed consent Exclusion Criteria: 1. Participants were diagnosed with parkinsonism-syndrome 2. Participants were treated with antiparkinsonian drugs at baseline 3. Participants with cognitive impairment 4. Unable to Written informed consent
Where this trial is running
Changsha, Hunan
- Xiangya Hospital of Central South University — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Jifeng Guo, Ph.D
- Email: guojifeng2003@163.com
- Phone: +8613974936815
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.